Cited 6 times in
Clinical implication and usefulness of de novo EGFR T790M mutation in lung adenocarcinoma with EGFR-tyrosine kinase inhibitor sensitizing mutation
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이상훈 | - |
dc.contributor.author | 김은영 | - |
dc.contributor.author | 장윤수 | - |
dc.date.accessioned | 2020-10-05T00:59:00Z | - |
dc.date.available | 2020-10-05T00:59:00Z | - |
dc.date.issued | 2020-08 | - |
dc.identifier.issn | 1538-4047 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/179715 | - |
dc.description.abstract | In total, 102 cases diagnosed as lung adenocarcinoma with EGFR-tyrosine kinase inhibitor (TKI) sensitizing mutations (mEGFR) and had been treated with 1st ~ 2nd generation EGFR-TKI alone were enrolled for this study. De novo T790 M status was tested using the tissues at the initial diagnosis and positivity was defined as the ratio of T790 M/wild-type copies over 0.00294 by ddPCR.Seventy patients (68.6%) harbored the de novo T790 M. De novo T790 M was more frequently detected in cases with EGFR L858 R mutation than those with EGFR exon 19 deletion (E19d) mutations (P = 0.024). Forty-three patients underwent rebiopsy due to disease progression. The cases who experienced progression due to acquired T790 M were more likely to have E19d at initial diagnosis and the presence of de novo T790 M and the ratio of T790 M/wild-type copies did not relate to the emergence of acquired T790 M. On the other hand, the cases with a longer duration of disease-control by EGFR-TKI had higher change to get acquired T790 M mutation (P-value = 0.040).The presence of de novo T790 M has limitation in predicting disease progression by acquired T790 M, suggesting that identifying de novo T790 M through the ultrasensitive methods may not be necessary identifying patients who would be beneficial by 3rd-generation EGFR-TKI as the 1st line treatment. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Taylor & Francis | - |
dc.relation.isPartOf | CANCER BIOLOGY & THERAPY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Clinical implication and usefulness of de novo EGFR T790M mutation in lung adenocarcinoma with EGFR-tyrosine kinase inhibitor sensitizing mutation | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Sang Hoon Lee | - |
dc.contributor.googleauthor | Eun Young Kim | - |
dc.contributor.googleauthor | Arum Kim | - |
dc.contributor.googleauthor | Yoon Soo Chang | - |
dc.identifier.doi | 10.1080/15384047.2020.1776579 | - |
dc.contributor.localId | A02836 | - |
dc.contributor.localId | A00811 | - |
dc.contributor.localId | A03456 | - |
dc.relation.journalcode | J00435 | - |
dc.identifier.eissn | 1555-8576 | - |
dc.identifier.pmid | 32543264 | - |
dc.identifier.url | https://www.tandfonline.com/doi/full/10.1080/15384047.2020.1776579 | - |
dc.subject.keyword | De novo T790M mutation | - |
dc.subject.keyword | droplet digital polymerase chain reaction (ddPCR) | - |
dc.subject.keyword | epidermal growth factor receptor-tyrosine kinase inhibitor sensitizing mutation | - |
dc.subject.keyword | lung adenocarcinoma | - |
dc.contributor.alternativeName | Lee, Sang Hoon | - |
dc.contributor.affiliatedAuthor | 이상훈 | - |
dc.contributor.affiliatedAuthor | 김은영 | - |
dc.contributor.affiliatedAuthor | 장윤수 | - |
dc.citation.volume | 21 | - |
dc.citation.number | 8 | - |
dc.citation.startPage | 741 | - |
dc.citation.endPage | 748 | - |
dc.identifier.bibliographicCitation | CANCER BIOLOGY & THERAPY, Vol.21(8) : 741-748, 2020-08 | - |
dc.identifier.rimsid | 67227 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.